Inhaled corticosteroid dose-reducing effect of omalizumab in patients with controlled, severe asthma according to usage of inhaled long-acting beta-agonists

2002 ◽  
Vol 109 (1) ◽  
pp. S239-S239 ◽  
Author(s):  
Kian Fan Chung ◽  
Stephen Holgate ◽  
John O'Brien ◽  
Howard Fox ◽  
Jackie Thirlwell
Keyword(s):  
Severe Asthma ◽  
Inhaled Corticosteroid ◽  
Corticosteroid Dose ◽  
Beta Agonists ◽  
Long Acting

scholarly journals Algorithm of biophenotyping and choice of medication for targeted therapy of severe uncontrolled asthma with eosinophilic type of airways inflammation

2017 ◽  
Vol 14 (3) ◽  
pp. 5-18
Author(s):  
N I Ilina ◽  
N M Nenasheva ◽  
S N Avdeev ◽  
Z R Aisanov ◽  
V V Arkhipov ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Clinical Studies ◽  
Inhaled Corticosteroids ◽  
Uncontrolled Asthma ◽  
Treatment Regimens ◽  
Expert Opinions ◽  
Beta Agonists ◽  
Biomarker Testing ◽  
High Doses ◽  
Long Acting

The article is based on the resolution of the Expert Council, including experts from Russian Association of Allergists and Clinical Immunologists (RAACI) and Russian Respiratory Society (RRS) dated November 20, 2016, and the review of clinical studies results and publications on the biomarker-based diagnosis and biological treatment of severe uncontrolled asthma. The aim of this work is to develop a phenotype-oriented algorithm of diagnostics and treatment of severe asthma, supported by the biomarker testing for subsequent selection of appropriate immunobiological treatment. The article constitutes the summary of results of clinical studies and expert opinions on the treatment of asthma in patients who do not achieve disease control with standard treatment regimens including high doses of inhaled corticosteroids in the combination with long-acting beta-agonists, tiotropium, and medications from other pharmacological groups according to Russian Respiratory Society (2016) and GINA (2016-2017) guidelines. The article summarizes the results of international randomized clinical studies performed to assess safety and efficacy of new class of biological treatments, monoclonal antibodies acting against major cytokines that are responsible for inflammation, in patients with severe asthma, including a new anti-IL-5 antibody, reslizumab (Cinqaero).

The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality

2016 ◽  
Vol 26 (4) ◽  
pp. 446-458
Author(s):  
Catherine B. Johannes ◽  
Lisa J. McQuay ◽  
Kirk D. Midkiff ◽  
Brian Calingaert ◽  
Elizabeth B. Andrews ◽  
...  
Keyword(s):  
Corticosteroid Therapy ◽  
Potential Effect ◽  
Inhaled Corticosteroid ◽  
Beta Agonists ◽  
Long Acting ◽  
Asthma Mortality

Pharmacology Update: Emergency and Controller Medications for Treatment of Asthma

2021 ◽  
pp. 1942602X2110369
Author(s):  
Anil Nanda ◽  
Anne F. Russell ◽  
Theresa A. Bingemann
Keyword(s):  
The United States ◽  
Dose Inhaler ◽  
Inhaled Corticosteroid ◽  
Multiple Forms ◽  
Beta Agonists ◽  
Metered Dose ◽  
Long Acting ◽  
Controller Medications ◽  
Fast Acting ◽  
Chronic Childhood

Asthma is the most common noncommunicable chronic childhood disease, affecting more than 5 million children in the United States. Asthma is the leading cause of school absenteeism. Treatments for asthma are divided into fast-acting medications that are used to relieve symptoms and slower acting (controller) medications that prevent symptoms. Albuterol is the most common fast acting medication for asthma, and it exists in multiple forms, including metered-dose inhaler and nebulized therapy. The use of spacers and holding chambers can further improve medication deposition in the airway. The cornerstone controller therapy for asthma is inhaled corticosteroid. Other medications for asthma include long-acting beta agonists, long-acting antimuscarinics, and antileukotrienes. The newest agents for controller asthma therapies are biologics.

Sign in / Sign up

Export Citation Format

Share Document